Search results
Jun 11, 2024 · Kyowa Kirin Inc. has announced plans to invest up to $530 million in a new manufacturing facility in Sanford, North Carolina. The 171,700-square-foot, two-reactor facility will enhance the company’s development and production of biologic therapies for patients with rare and serious diseases.
Jun 14, 2024 · Dive Brief: Japan-based pharmaceutical company Kyowa Kirin plans to invest up to $530 million to build a new biologic therapies manufacturing facility in Sanford, North Carolina.
Jun 13, 2024 · Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin), a global specialty pharmaceutical company based in Japan, this week announced that its board of directors approved plans to invest up to $530 million to build a new, state-of-the-art manufacturing facility in Sanford, N.C.
Jun 10, 2024 · Company's first manufacturing facility in North America to accelerate production of new biologic. therapies to advance clinical pipeline. Facility to draw upon local talent, area colleges and ...
Jun 10, 2024 · Company's first manufacturing facility in North America to accelerate production of new biologic therapies to advance clinical pipeline. Facility to draw upon local talent, area colleges and ...
6 days ago · Kyowa Kirin, a pharmaceutical company based in Japan, will build a new biologics manufacturing facility in Sanford, North Carolina, expanding its worldwide manufacturing presence in North America. The facility will produce cutting-edge biologic therapies, such as next-generation antibodies, for the company’s upcoming clinical trials and future commercial purposes.
Jun 10, 2024 · Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE: 4151), a global specialty pharmaceutical company based in Japan, today announced that its board of directors has...